NCT05442632View on ClinicalTrials.gov

Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy

PHASE2RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

July 25, 2022

Primary Completion Date

December 1, 2025

Study Completion Date

December 30, 2025

Conditions
Hepatopathy
Interventions
DRUG

Hetrombopag

The patients received Hetrombopag 5mg orally d1-14 days, surgery will be conducted at d6-14 day

DRUG

Placebo

The patients received Placebo 5mg orally d1-14 days, surgery will be conducted at d6-14 day

Trial Locations (1)

200062

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER